The National Institutes of Health (NIH) has awarded Ohio’s Tulane University $2.6 million to fund new research on the hepatitis C virus (HCV) and how infected patients respond to therapy, The Associated Press reports. Srikanta Dash, PhD, professor of pathology at the university and the director of its hepatitis research lab, was awarded two separate grants. The first, totaling $1.4 million, will take four years to explore the genetic mechanisms behind a patient’s responsiveness to antiviral hepatitis C treatment. The second, totaling $1.2 million, will fund studies on how chronic hep C develops resistance to interferon therapies.

To read the article, click here.